NEW YORK — Prescient Medicine said this week that it has partnered with Dutch medical research institute Erasmus MC to evaluate its opioid addiction risk technology in a clinical study in the Netherlands.
Prescient offers a tes, called LifeKit Predict that is designed to determine an individual's risk of opioid addiction by analyzing 16 genes in the brain's reward pathway. The assay uses multiplexed PCR and nucleic acid hybridization to analyze DNA extracted from buccal swabs.